Critical Development Needs for Recombinant Blood-Coagulation Factors

O. B. Ustinnikova; O. B. Runova; E. V. Novikova; V. P. Bondarev; E. V. Lebedinskaya

doi:10.1007/s11094-016-1492-0

Critical Development Needs for Recombinant Blood-Coagulation Factors

作者: Ustinnikova O.B.¹, Runova O.B.¹, Novikova E.V.¹, Bondarev V.P.¹, Lebedinskaya E.V.¹
隶属关系:
1. State Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Public Health of the Russian Federation
期: 卷 50, 编号 9 (2016)
页面: 573-576
栏目: Molecular-Biological Problems of Drug Design and Mechanism of Drug Action
URL: https://ogarev-online.ru/0091-150X/article/view/244439
DOI: https://doi.org/10.1007/s11094-016-1492-0
ID: 244439

如何引用文章

全文:

开放存取

##reader.subscriptionAccessGranted##
受限制的访问

订阅存取

详细
作者简介
参考
补充文件
统计

详细

Critical development needs for recombinant blood-coagulation factors (RBCFs) are reviewed. The production of less immunogenic drugs with suppressed induction of inhibitory antibodies and prolonged therapeutic effects resulting from an increased inactivation threshold is demonstrated to be a major need for designing new RBCF modifications differing in structure and composition from endogenous blood-coagulation factors while retaining their activity.